Precision Biosensor프리시젼바이오
335810 · KOSDAQ · ₩335810 · 프리시젼바이오
₩1,435▲ ₩4 (0.28%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩20B | ₩19B | ₩20B | ₩20B | ₩16B |
| Cost of sales | ₩14B | ₩13B | ₩13B | ₩14B | ₩11B |
| Gross profit | ₩6.4B | ₩6.2B | ₩7.7B | ₩6.8B | ₩4.6B |
| Operating income | −₩5.4B | −₩5.4B | −₩4.8B | −₩4.5B | −₩4.3B |
| Net income | −₩10B | −₩7.3B | −₩4.5B | −₩6.8B | −₩4.2B |
| Net income to shareholders | −₩10B | −₩7.3B | −₩4.5B | −₩6.8B | −₩4.2B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩53B | ₩52B | ₩62B | ₩59B | ₩56B |
| Current assets | ₩23B | ₩16B | ₩18B | ₩21B | ₩33B |
| Cash and equivalents | ₩3.3B | ₩1.7B | ₩2.4B | ₩7.6B | ₩5.5B |
| Total liabilities | ₩20B | ₩26B | ₩30B | ₩26B | ₩17B |
| Current liabilities | ₩18B | ₩19B | ₩13B | ₩20B | ₩2.2B |
| Borrowings | ₩13B | ₩16B | ₩18B | ₩14B | ₩9.3B |
| Total equity | ₩33B | ₩26B | ₩32B | ₩33B | ₩38B |
| Shareholders' equity | ₩33B | ₩26B | ₩32B | ₩33B | ₩38B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩1.5B | −₩1.4B | −₩2B | −₩2.6B | −₩4.6B |
| Capital spending | ₩157M | ₩65M | ₩7.1B | ₩11B | ₩9.2B |
| Free cash flow | −₩1.7B | −₩1.5B | −₩9B | −₩14B | −₩14B |
Consolidated where available. Amounts in won.
Also known as: Precision Biosensor / 프리시젼바이오 / 335810 / KRX:335810
Source: KRX statistical information